Shares of Indaptus Therapeutics (Nasdaq: INDP) are rallying premarket after news that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company’s platform technology.
A notice of allowance is a letter of notification from the US Patent and Trademark Office that says a mark has got through the opposition period after publication in the Official Gazette and has been allowed. However, it does not mean the trademark has been registered yet.
Indaptus' patent is titled, “Methods of Treatment of Infections Using Bacteria.” It provides protection for applying the company’s platform technology alone and in combination with standards of care for treating and inhibiting hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
“We are delighted to expand our growing patent estate and this notice of allowance provides further validation of the novel approach of our Indaptus platform technology as it relates to viral infections,” said Dr Michael Newman, Founder and Chief Scientific Officer of Indaptus Therapeutics.
Premarket, Indaptus Therapeutics shares are up 38.61% at $9.80, erasing September's losses.
Should You Invest in Indaptus Therapeutics Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now